膀胱癌分子生物学标志物的研究进展  

Research Progress of Molecular Biomarkers for Bladder Cancer

作　　者：张佳伟[1] 祝清国[1] 

机构地区：[1]哈尔滨医科大学附属第二医院泌尿外科,哈尔滨150080

出　　处：《医学综述》2017年第9期1742-1746,共5页Medical Recapitulate

摘　　要：膀胱癌是目前最常见的泌尿系恶性肿瘤,具有较高的发病率与病死率,已成为我国重要的公共卫生事件。目前膀胱镜检查和尿脱落细胞学仍是膀胱癌诊断的金标准。但随着检测技术不断进步,膀胱癌分子生物学标志物逐渐成为诊断膀胱癌的新标准。同时,通过对膀胱癌分子生物学标志物的研究,还能给临床医师带来肿瘤发病情况的实时信息,并很有可能改变目前临床医师对膀胱癌诊治的认识。Bladder cancer is the most common urinary tract malignancy, which has a high morbidity and mortality, and has become an important public health event. At present, cystoscopy and urine exfoliative cytology are still the gold standard for bladder cancer diagnosis. However, with the continuous improvement of detection technology, molecular markers of bladder cancer has gradually become a new standard for diagnosis of bladder cancer. At the same time, the research on the molecular biological markers of bladder.cancercan also provide real-time information of the cancer condition, and is likely to change the current understanding of the diagnosis and treatment of bladder cancer of the clinicians.

关 键 词：膀胱癌 分子生物学标志物 致癌基因 微RNA 循环肿瘤细胞 

分 类 号：R737.14[医药卫生—肿瘤]